Similar articles for PMID: 28146658

Year	Number of Results
1995	1
1996	3
1997	1
1998	4
2000	2
2001	1
2002	6
2003	3
2004	8
2005	6
2006	6
2007	14
2008	10
2009	11
2010	7
2011	8
2012	18
2013	15
2014	15
2015	6
2016	9
2017	4
2018	9
2019	15
2020	19
2021	15
2022	19
2023	7
2024	0

1

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.

Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM; NRG Oncology RTOG. Shipley WU, et al. N Engl J Med. 2017 Feb 2;376(5):417-428. doi: 10.1056/NEJMoa1607529. N Engl J Med. 2017. PMID: 28146658 Free PMC article. Clinical Trial.

2

A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.

Chu FM, Sartor O, Gomella L, Rudo T, Somerville MC, Hereghty B, Manyak MJ. Chu FM, et al. Eur J Cancer. 2015 Aug;51(12):1555-69. doi: 10.1016/j.ejca.2015.04.028. Epub 2015 Jun 2. Eur J Cancer. 2015. PMID: 26048455 Clinical Trial.

3

Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression.

Wirth M, Tyrrell C, Wallace M, Delaere KP, Sánchez-Chapado M, Ramon J, Hetherington J, Pina F, Heynes CF, Borchers TM, Morris T, Stone A. Wirth M, et al. Urology. 2001 Aug;58(2):146-51. doi: 10.1016/s0090-4295(01)01213-4. Urology. 2001. PMID: 11489683 Clinical Trial.

4

Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years.

Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP; Casodex Early Prostate Cancer Trialists' Group. Iversen P, et al. BJU Int. 2010 Apr;105(8):1074-81. doi: 10.1111/j.1464-410X.2010.09319.x. BJU Int. 2010. PMID: 22129214 Clinical Trial.

5

The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.

See WA, Tyrrell CJ; CASODEX Early Prostate Cancer Trialists' Group. See WA, et al. J Cancer Res Clin Oncol. 2006 Aug;132 Suppl 1:S7-16. doi: 10.1007/s00432-006-0132-6. J Cancer Res Clin Oncol. 2006. PMID: 16896884 Clinical Trial.

6

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.

McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP; Casodex Early Prostate Cancer Trialists' Group. McLeod DG, et al. BJU Int. 2006 Feb;97(2):247-54. doi: 10.1111/j.1464-410X.2005.06051.x. BJU Int. 2006. PMID: 16430622 Clinical Trial.

7

PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer.

McPartlin AJ, Glicksman R, Pintilie M, Tsuji D, Mok G, Bayley A, Chung P, Bristow RG, Gospodarowicz MK, Catton CN, Milosevic M, Warde PR. McPartlin AJ, et al. Cancer. 2016 Aug 15;122(16):2595-603. doi: 10.1002/cncr.30093. Epub 2016 May 24. Cancer. 2016. PMID: 27219522 Free article. Clinical Trial.

8

Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study.

Thomsen FB, Brasso K, Christensen IJ, Johansson JE, Angelsen A, Tammela TL, Iversen P; Scandinavian Prostate Cancer Group. Thomsen FB, et al. Eur J Cancer. 2015 Jul;51(10):1283-92. doi: 10.1016/j.ejca.2015.03.021. Epub 2015 Apr 16. Eur J Cancer. 2015. PMID: 25892647 Clinical Trial.

9

Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.

Fradet Y, Egerdie B, Andersen M, Tammela TL, Nachabe M, Armstrong J, Morris T, Navani S. Fradet Y, et al. Eur Urol. 2007 Jul;52(1):106-14. doi: 10.1016/j.eururo.2007.01.031. Epub 2007 Jan 16. Eur Urol. 2007. PMID: 17270340 Clinical Trial.

10

Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.

Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I, Supiot S, Bosset M, Lagrange JL, Beckendorf V, Lesaunier F, Dubray B, Wagner JP, N'Guyen TD, Suchaud JP, Créhange G, Barbier N, Habibian M, Ferlay C, Fourneret P, Ruffion A, Dussart S. Carrie C, et al. Lancet Oncol. 2016 Jun;17(6):747-756. doi: 10.1016/S1470-2045(16)00111-X. Epub 2016 May 6. Lancet Oncol. 2016. PMID: 27160475 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

212 results

Results by year